Literature DB >> 1558973

Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989.

R A Kyle1, A Linos, C M Beard, R P Linke, M A Gertz, W M O'Fallon, L T Kurland.   

Abstract

No reports of the incidence rates for primary systemic amyloidosis (AL) have come to our attention. Records of all residents of Olmstead County, Minnesota, with a diagnosis of amyloidosis were obtained from the Mayo Clinic and its affiliated hospitals, as well as other medical groups that might have seen local patients for the period January 1, 1950 to December 31, 1989. Twenty-one patients fulfilled the criteria for the diagnosis of AL. The median age was 73.5 years, and 62% were men. In all but one patient the diagnosis was made ante mortem. The clinical data of the 21 patients were similar to those referral patients with AL seen at Mayo Clinic. Immunohistochemical stains were positive for monoclonal light chains in the amyloid deposits in 15 of the 21 cases. In six cases, tissue was not available for immunohistochemical studies. Three of the six patients without immunohistochemical stains had a free monoclonal lambda light chain in the urine, and the other three had a monoclonal serum protein. Immunoelectrophoresis/immunofixation detected a monoclonal (M)-protein in the serum of 16 of 17 patients tested. A monoclonal light chain was found in the urine of 10 of 15 patients. The overall sex- and age-adjusted rate per million person-years was 6.1 from 1950 to 1969 and 10.5 from 1970 to 1989. The similarity of these rates suggests no significant increase over time.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1558973

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  145 in total

1.  [Systemic amyloidoses].

Authors:  S Schönland; N Blank; A V Kristen; J Beimler; T Ganten; U Hegenbart
Journal:  Internist (Berl)       Date:  2012-01       Impact factor: 0.743

2.  Role of high-dose melphalan and autologous peripheral blood stem cell transplantation in AL amyloidosis.

Authors:  Vaishali Sanchorawala
Journal:  Am J Blood Res       Date:  2012-01-01

3.  Robert Arthur Kyle, MD: a conversation with the editor.

Authors:  Robert Arthur Kyle; William Clifford Roberts
Journal:  Proc (Bayl Univ Med Cent)       Date:  2010-10

4.  Comparison of amyloid fibril formation by two closely related immunoglobulin light chain variable domains.

Authors:  Douglas J Martin; Marina Ramirez-Alvarado
Journal:  Amyloid       Date:  2010-09       Impact factor: 7.141

5.  A new isoleucine substitution of Val-20 in transthyretin tetramers selectively impairs dimer-dimer contacts and causes systemic amyloidosis.

Authors:  D E Jenne; K Denzel; P Blätzinger; P Winter; B Obermaier; R P Linke; K Altland
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

Review 6.  Daratumumab for the treatment of AL amyloidosis.

Authors:  M Hasib Sidiqi; Morie A Gertz
Journal:  Leuk Lymphoma       Date:  2018-07-22

7.  Etanercept therapy in patients with advanced primary amyloidosis.

Authors:  M A Hussein; J V Juturi; L Rybicki; S Lutton; B R Murphy; M A Karam
Journal:  Med Oncol       Date:  2003       Impact factor: 3.064

Review 8.  Secondary intestinal amyloidosis presenting intractable hematochezia: a case report and literature review.

Authors:  So Hyun Kim; Jae Hwang Kim; Mi Jin Gu
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15

Review 9.  Paraprotein-Related Kidney Disease: Kidney Injury from Paraproteins-What Determines the Site of Injury?

Authors:  Mona Doshi; Amit Lahoti; Farhad R Danesh; Vecihi Batuman; Paul W Sanders
Journal:  Clin J Am Soc Nephrol       Date:  2016-08-15       Impact factor: 8.237

Review 10.  Paraprotein-Related Kidney Disease: Glomerular Diseases Associated with Paraproteinemias.

Authors:  Shveta S Motwani; Leal Herlitz; Divya Monga; Kenar D Jhaveri; Albert Q Lam
Journal:  Clin J Am Soc Nephrol       Date:  2016-08-15       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.